- Home
- MDAI vs DRRX Comparison
MDAI vs DRRX Comparison
Compare MDAI & DRRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDAI
- DRRX
- Stock Information
- Founded
- MDAI 2013
- DRRX 1998
- Country
- MDAI United States
- DRRX United States
- Employees
- MDAI N/A
- DRRX N/A
- Industry
- MDAI Medical/Dental Instruments
- DRRX Biotechnology: Pharmaceutical Preparations
- Sector
- MDAI Health Care
- DRRX Health Care
- Exchange
- MDAI Nasdaq
- DRRX Nasdaq
- Market Cap
- MDAI 69.0M
- DRRX 59.3M
- IPO Year
- MDAI N/A
- DRRX 2000
- Fundamental
- Price
- MDAI $1.91
- DRRX $1.94
- Analyst Decision
- MDAI Strong Buy
- DRRX Hold
- Analyst Count
- MDAI 1
- DRRX 1
- Target Price
- MDAI $3.50
- DRRX N/A
- AVG Volume (30 Days)
- MDAI 351.9K
- DRRX 463.1K
- Earning Date
- MDAI 08-12-2025
- DRRX 08-12-2025
- Dividend Yield
- MDAI N/A
- DRRX N/A
- EPS Growth
- MDAI N/A
- DRRX N/A
- EPS
- MDAI N/A
- DRRX N/A
- Revenue
- MDAI $27,549,000.00
- DRRX $1,657,000.00
- Revenue This Year
- MDAI N/A
- DRRX N/A
- Revenue Next Year
- MDAI $60.05
- DRRX $673.00
- P/E Ratio
- MDAI N/A
- DRRX N/A
- Revenue Growth
- MDAI 22.27
- DRRX N/A
- 52 Week Low
- MDAI $0.82
- DRRX $0.48
- 52 Week High
- MDAI $3.25
- DRRX $2.64
- Technical
- Relative Strength Index (RSI)
- MDAI 33.85
- DRRX 79.08
- Support Level
- MDAI $1.98
- DRRX $1.86
- Resistance Level
- MDAI $2.14
- DRRX $1.96
- Average True Range (ATR)
- MDAI 0.14
- DRRX 0.03
- MACD
- MDAI -0.02
- DRRX -0.04
- Stochastic Oscillator
- MDAI 11.36
- DRRX 80.00
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
About DRRX DURECT Corporation
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories, which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from Europe.